Article
Specific targeting of MR1-antigen complexes using nanobodies
2026-03-25
Abstract excerpt
T cell receptor mimic (TCRm) antibodies and nanobodies that specifically bind peptide-HLA complexes have great therapeutic potential, as they can target polymorphic HLA on tumour cells furnishing peptides derived from tumour-associated antigens. MR1 is an MHC class-I-like molecule that exhibits limited polymorphism that binds and presents conserved metabolites, such as 5-OP-RU, derived from microbial riboflavin bi...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1c561f12-ce08-536c-87d8-3ea4a3fd699c
- DOI
- 10.64898/2026.03.22.713551
